Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair.
DNA repair
HDAC
JQ1
RAD51
apoptosis
chondrosarcoma
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
03
2020
accepted:
18
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
Chondrosarcoma is the second-most common type of bone tumor and has inherent resistance to conventional chemotherapy. Present study aimed to explore the therapeutic effect and specific mechanism(s) of combination BET family protein and HDAC inhibition in chondrosarcoma. Two chondrosarcoma cells were treated with BET family protein inhibitor (JQ1) and histone deacetylase inhibitors (HDACIs) (vorinostat/SAHA or panobinostat/PANO) separately or in combination; then, the cell viability was determined by Cell Counting Kit-8 (CCK-8) assay, and the combination index (CI) was calculated by the Chou method; cell proliferation was evaluated by 5-ethynyl-2'-deoxyuridine (EdU) incorporation and colony formation assay; cell apoptosis and reactive oxygen species (ROS) level were determined by flow cytometry; protein expressions of caspase-3, Bcl-XL, Bcl-2, γ-H2AX, and RAD51 were examined by Immunoblotting; DNA damage was determined by comet assay; RAD51 and γ-H2AX foci were observed by immunofluorescence. Combined treatment with JQ1 and SAHA or PANO synergistically suppressed the growth and colony formation ability of the chondrosarcoma cells. Combined BET and HDAC inhibition also significantly elevated the ROS level, followed by the activation of cleaved-caspase-3, and the downregulation of Bcl-2 and Bcl-XL. Mechanistically, combination treatment with JQ1 and SAHA caused numerous DNA double-strand breaks (DSBs), as evidenced by the comet assay. The increase in γ-H2AX expression and foci formation also consistently indicated the accumulation of DNA damage upon cotreatment with JQ1 and SAHA. Furthermore, RAD51, a key protein of homologous recombination (HR) DNA repair, was found to be profoundly suppressed. In contrast, ectopic expression of RAD51 partially rescued SW 1353 cell apoptosis by inhibiting the expression of cleaved-caspase-3. Taken together, our results disclose that BET and HDAC inhibition synergistically inhibit cell growth and induce cell apoptosis through a mechanism that involves the suppression of RAD51-related HR DNA repair in chondrosarcoma cells.
Sections du résumé
BACKGROUND
BACKGROUND
Chondrosarcoma is the second-most common type of bone tumor and has inherent resistance to conventional chemotherapy. Present study aimed to explore the therapeutic effect and specific mechanism(s) of combination BET family protein and HDAC inhibition in chondrosarcoma.
METHODS
METHODS
Two chondrosarcoma cells were treated with BET family protein inhibitor (JQ1) and histone deacetylase inhibitors (HDACIs) (vorinostat/SAHA or panobinostat/PANO) separately or in combination; then, the cell viability was determined by Cell Counting Kit-8 (CCK-8) assay, and the combination index (CI) was calculated by the Chou method; cell proliferation was evaluated by 5-ethynyl-2'-deoxyuridine (EdU) incorporation and colony formation assay; cell apoptosis and reactive oxygen species (ROS) level were determined by flow cytometry; protein expressions of caspase-3, Bcl-XL, Bcl-2, γ-H2AX, and RAD51 were examined by Immunoblotting; DNA damage was determined by comet assay; RAD51 and γ-H2AX foci were observed by immunofluorescence.
RESULTS
RESULTS
Combined treatment with JQ1 and SAHA or PANO synergistically suppressed the growth and colony formation ability of the chondrosarcoma cells. Combined BET and HDAC inhibition also significantly elevated the ROS level, followed by the activation of cleaved-caspase-3, and the downregulation of Bcl-2 and Bcl-XL. Mechanistically, combination treatment with JQ1 and SAHA caused numerous DNA double-strand breaks (DSBs), as evidenced by the comet assay. The increase in γ-H2AX expression and foci formation also consistently indicated the accumulation of DNA damage upon cotreatment with JQ1 and SAHA. Furthermore, RAD51, a key protein of homologous recombination (HR) DNA repair, was found to be profoundly suppressed. In contrast, ectopic expression of RAD51 partially rescued SW 1353 cell apoptosis by inhibiting the expression of cleaved-caspase-3.
CONCLUSION
CONCLUSIONS
Taken together, our results disclose that BET and HDAC inhibition synergistically inhibit cell growth and induce cell apoptosis through a mechanism that involves the suppression of RAD51-related HR DNA repair in chondrosarcoma cells.
Identifiants
pubmed: 32606937
doi: 10.2147/CMAR.S254412
pii: 254412
pmc: PMC7294047
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4429-4439Informations de copyright
© 2020 Huan et al.
Déclaration de conflit d'intérêts
All authors have declared no conflicts of interest.
Références
Redox Biol. 2014 Jan 09;2:457-65
pubmed: 24624335
EBioMedicine. 2019 Jun;44:419-430
pubmed: 31126889
Trends Cell Biol. 2016 Jan;26(1):52-64
pubmed: 26437586
Clin Epigenetics. 2010 Dec;1(3-4):117-136
pubmed: 21258646
Future Oncol. 2017 Mar;13(7):637-648
pubmed: 28133974
Oncogene. 2014 May 1;33(18):2395-404
pubmed: 23686307
J Clin Endocrinol Metab. 2009 Jan;94(1):164-70
pubmed: 18854394
Stem Cell Reports. 2017 Jan 10;8(1):125-139
pubmed: 28076755
J Thorac Oncol. 2013 Mar;8(3):279-86
pubmed: 23399959
Clin Cancer Res. 2008 Nov 1;14(21):7138-42
pubmed: 18981013
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Int J Cancer. 2019 Feb 15;144(4):755-766
pubmed: 30259975
Cancer Lett. 2018 Aug 1;428:160-172
pubmed: 29709701
Cell Death Dis. 2013 Feb 28;4:e519
pubmed: 23449455
Int J Cancer. 2017 Oct 1;141(7):1286-1294
pubmed: 28477336
Oncogenesis. 2016 May 09;5:e222
pubmed: 27159675
Science. 2018 May 18;360(6390):713-714
pubmed: 29773735
Clin Epigenetics. 2018 Jan 4;10:1
pubmed: 29312470
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7
pubmed: 18042714
Clin Cancer Res. 2007 Jan 1;13(1):275-82
pubmed: 17200366
Cancer Cell. 2018 Mar 12;33(3):401-416.e8
pubmed: 29533782
Neuro Oncol. 2015 Jun;17(6):862-7
pubmed: 25572329
Philos Trans R Soc Lond B Biol Sci. 2004 Jan 29;359(1441):87-93
pubmed: 15065660
J Cell Physiol. 2020 Apr;235(4):3894-3904
pubmed: 31595984
Cell Immunol. 2019 Mar;337:48-53
pubmed: 30832981
J Exp Clin Cancer Res. 2018 Oct 1;37(1):241
pubmed: 30285808
Cell. 2013 Apr 11;153(2):320-34
pubmed: 23582323
BMC Cancer. 2017 Dec 18;17(1):864
pubmed: 29254481
Ann Oncol. 2012 Jun;23(6):1617-26
pubmed: 22112972
Clin Cancer Res. 2016 May 15;22(10):2534-44
pubmed: 26733615
Drug Discov Today Technol. 2016 Mar;19:45-50
pubmed: 27769357
Future Oncol. 2011 Feb;7(2):263-83
pubmed: 21345145
Crit Rev Oncol Hematol. 2018 Jun;126:32-36
pubmed: 29759564
Ann Oncol. 2013 Nov;24(11):2916-22
pubmed: 24099780
Sarcoma. 2011;2011:381564
pubmed: 21234363
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Mol Cancer Ther. 2014 May;13(5):1142-54
pubmed: 24435446
Apoptosis. 2000 Nov;5(5):415-8
pubmed: 11256882
J Cell Biochem. 2017 Aug;118(8):2182-2192
pubmed: 28059436
FEBS J. 2016 Jan;283(2):232-45
pubmed: 26507796
PLoS One. 2014 Jan 23;9(1):e87003
pubmed: 24466310
Front Genet. 2015 Apr 23;6:157
pubmed: 25954303
Curr Opin Oncol. 2016 Jul;28(4):314-22
pubmed: 27166664
J Exp Clin Cancer Res. 2018 Jul 16;37(1):153
pubmed: 30012171
Cancer Treat Rev. 2017 Sep;59:33-45
pubmed: 28732326
Biochim Biophys Acta. 2014 Nov;1839(11):1330-40
pubmed: 25281873
Cancer. 2014 Oct 15;120(20):3159-64
pubmed: 24995550